We developed a cancer exosome nanovesicles‐assisted therapeutic strategy to specifically deliver two biocompatible components for local immunometabolic therapy: a CD39 inhibitor POM1 and AMPK agonist metformin. This evidence concerns the gene ENTPD1 and cancer.